blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3891162

EP3891162 - NOVEL DERIVATIVES OF N-3"-GUANIDINO-2,5-DIDEOXY-5-FLUORO-4,6-DISUBSTITUTED-STREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS [Right-click to bookmark this link]
Former [2021/41]NOVEL ANTIBACTERIAL 3"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS
[2022/41]
StatusThe patent has been granted
Status updated on  02.02.2024
Database last updated on 19.10.2024
FormerGrant of patent is intended
Status updated on  13.09.2023
FormerRequest for examination was made
Status updated on  10.02.2023
FormerGrant of patent is intended
Status updated on  29.09.2022
FormerRequest for examination was made
Status updated on  10.09.2021
FormerThe international publication has been made
Status updated on  13.06.2020
Formerunknown
Status updated on  11.12.2019
Most recent event   Tooltip18.10.2024Lapse of the patent in a contracting state
New state(s): PT, SM		published on 20.11.2024 [2024/47]
Applicant(s)For all designated states
AGILeBiotics B.V.
L.J. Zielstraweg 2
9713 GX Groningen / NL
[2024/09]
Former [2021/41]For all designated states
AGILeBiotics B.V.
De Mudden 14
9747 AW Groningen / NL
Inventor(s)01 / BASTIAN, Andreas Alexander
AGILeBiotics B.V. De Mudden 14
9747 AW Groningen / NL
02 / BASTIAN, Maria
AGILeBiotics B.V. De Mudden 14
9747 AW Groningen / NL
 [2021/41]
Representative(s)dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
[2021/41]
Application number, filing date19813334.005.12.2019
[2021/41]
WO2019EP83784
Priority number, dateEP2018021047005.12.2018         Original published format: EP 18210470
[2021/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020115190
Date:11.06.2020
Language:EN
[2020/24]
Type: A1 Application with search report 
No.:EP3891162
Date:13.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 11.06.2020 takes the place of the publication of the European patent application.
[2021/41]
Type: B1 Patent specification 
No.:EP3891162
Date:06.03.2024
Language:EN
[2024/10]
Search report(s)International search report - published on:EP11.06.2020
ClassificationIPC:C07H15/234, A61K31/7036, A61P31/00
[2021/41]
CPC:
C07D487/04 (EP); C07H15/234 (EP,US); A61P31/04 (US);
Y02A50/30 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/41]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:NEUARTIGE DERIVATE VON 4,6-DISUBSTITUIERTEN-2,5-DIDEOXY-5-FLUORO-STREPTAMIN- N-3''-GUANIDINO-AMINOGLYKOSID-ANTIBIOTIKA[2022/41]
English:NOVEL DERIVATIVES OF N-3"-GUANIDINO-2,5-DIDEOXY-5-FLUORO-4,6-DISUBSTITUTED-STREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS[2022/41]
French:NOUVEAUX DÉRIVÉS D'ANTIBIOTIQUES AMINOGLYCOSIDES À BASE DE N-3''-GUANIDINO- 2,5-DIDÉSOXY-5-FLUORO-STREPTAMINE-4,6-DISUBSTITUÉS[2022/31]
Former [2021/41]NEUARTIGE ANTIBAKTERIELLE 3''-DERIVATE VON 4,6-DISUBSTITUIERTEN 2,5-DIDEOXYSTREPTAMIN-AMINOGLYKOSID-ANTIBIOTIKA
Former [2021/41]NOVEL ANTIBACTERIAL 3"-DERIVATIVES OF 4,6-DISUBSTITUTED 2,5-DIDEOXYSTREPTAMINE AMINOGLYCOSIDE ANTIBIOTICS
Former [2021/41]NOUVEAUX DÉRIVÉS 3" ANTIBACTÉRIENS D'ANTIBIOTIQUES À BASE D'AMINOGLYCOSIDE 2,5-DIDÉSOXYSTREPTAMINE 4,6-DISUBSTITUÉS
Entry into regional phase05.07.2021National basic fee paid 
05.07.2021Designation fee(s) paid 
05.07.2021Examination fee paid 
Examination procedure05.07.2021Examination requested  [2021/41]
05.07.2021Date on which the examining division has become responsible
30.09.2022Communication of intention to grant the patent
09.02.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
14.09.2023Communication of intention to grant the patent
24.01.2024Fee for grant paid
24.01.2024Fee for publishing/printing paid
24.01.2024Receipt of the translation of the claim(s)
Fees paidRenewal fee
28.12.2021Renewal fee patent year 03
19.05.2023Renewal fee patent year 04
22.12.2023Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.12.202204   M06   Fee paid on   19.05.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
LV06.03.2024
NL06.03.2024
SE06.03.2024
SM06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
IS06.07.2024
PT08.07.2024
[2024/47]
Former [2024/46]BG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
LV06.03.2024
NL06.03.2024
SE06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
IS06.07.2024
Former [2024/41]BG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
LV06.03.2024
NL06.03.2024
SE06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
Former [2024/37]BG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
LV06.03.2024
SE06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
Former [2024/36]BG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
LV06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
Former [2024/35]BG06.03.2024
ES06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
Former [2024/34]BG06.03.2024
FI06.03.2024
HR06.03.2024
LT06.03.2024
NO06.06.2024
RS06.06.2024
GR07.06.2024
Former [2024/33]LT06.03.2024
NO06.06.2024
Cited inInternational search[AD]  - SHITARA T ET AL, "Synthesis of 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of kanamycin B in its analogs. Study on structure-toxicity relationships", CARBOHYDRATE RESEARCH, PERGAMON, GB, vol. 232, no. 2, doi:10.1016/0008-6215(92)80060-E, ISSN 0008-6215, (19920803), pages 273 - 290, (19920803), XP026634507 [AD] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/0008-6215(92)80060-E
 [AD]  - ANDRÉS G. SANTANA ET AL, "Selective modification of the 3''-amino group of kanamycin prevents significant loss of activity in resistant bacterial strains", ORGANIC & BIOMOLECULAR CHEMISTRY, (20160101), vol. 14, no. 2, doi:10.1039/C5OB01599E, ISSN 1477-0520, pages 516 - 525, XP055602559 [AD] 1-15 * the whole document * * In particular compound 7 and Conclusions *

DOI:   http://dx.doi.org/10.1039/C5OB01599E
by applicantWO2010132768
 US2013195149
 US2013217642
    - SANTANA, A. G.ZARATE, S. G.ASENSIO, J. L.REVUELTA, J.BASTIDA, A., "Selective modification of the 3''-amino group of kanamycin prevents significant loss of activity in resistant bacterial strains", Org, Biomol. Chem., (20160000), vol. 14, doi:10.1039/C5OB01599E, pages 516 - 525, XP055602559

DOI:   http://dx.doi.org/10.1039/C5OB01599E
    - T. TSUCHIYAT. SHITARAS. UMEZAWAT. TAKEUCHIM. HAMADAN. TOMONOE. UMEMURA, "Synthesis of low-toxicity, 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of arbekacin and its analogs, and study of structure-toxicity relationships", Carbohydr. Res., (19930000), vol. 240, doi:10.1016/0008-6215(93)84194-B, pages 307 - 312, XP026634814

DOI:   http://dx.doi.org/10.1016/0008-6215(93)84194-B
    - T. SHITARAY. KOBAYASHIT. TSUCHIYAS. UMEZAWA, "Synthesis of 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of kanamycin B and its analogs. Study on structure-toxicity relationships", Carbohydr. Res., (19920000), vol. 232, doi:10.1016/0008-6215(92)80060-E, pages 273 - 290, XP026634507

DOI:   http://dx.doi.org/10.1016/0008-6215(92)80060-E
    - X.-Z. LIP. PLESIATH. NIKAIDO, Clin. Microbiol. Rev., (20150000), vol. 28, no. 2, pages 337 - 418
    - J. SUNZ. DENGA. YAN, Biochem. Biophys. Res. Commun., (20140000), vol. 453, pages 254 - 267
    - ALI, B. H. et al., Basic and Clinical Pharmacology & Toxicology, vol. 109, pages 225 - 232
    - BALAKUMAR P. et al., Pharmacological Research, (20100000), vol. 62, pages 179 - 186
    - N. R. CONLEY, Organometallics, (20070000), vol. 26, no. 23, page 5447
    - G.-J. TEN BRINK, Adv. Synth. Catal., (20030000), vol. 345, page 1341
    - "GenBank", Database accession no. X55652.1
    - TRIEU-CUOT, Mol. Gen. Genet., (19850000), vol. 198, no. 2, page 348
    - S. B. VAKULENKO, J. Biol. Chem., (20120000), vol. 287, no. 52, page 43262
    - BIERMAN et al., Gene, (19920000), vol. 116, no. 1, page 43
    - M JUHAS et al., J. Antimicrob. Chemother., (20190000), vol. 74, no. 4, pages 944 - 952
    - D. HUGHES et al., Antimicrob. Agents Chemother., (20030000), vol. 47, no. 10, pages 3222 - 3232
    - M. E. FARKASB. C. LIC. DOSEP. B. DERVAN, Bioorg. & Med. Chem. Lett., (20090000), vol. 19, pages 3919 - 3923
    - JAEGER, M., "Selective oxidation of glycosides", Ph.D. thesis, (20150000), ISBN 978-90-367-7965-4, pages 83 - 130
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.